Table 1.
Comparison of HBsAg-positive patients with HBsAg-negative patients
| HBsAg-positive patients (No = 81)(30.9%) | HBsAg-negative patients (No = 181)(69.1%) | p-value | |
| Age (years) | 0.026 | ||
| Range | 17–75 | 17–86 | |
| Median | 46 | 51 | |
| Sex | 0.006 | ||
| Male | 41(50.6) | 124(68.5) | |
| Female | 40(49.4) | 57(31.5) | |
| Stage | 0.016 | ||
| I/II | 34(42) | 105 (58) | |
| III/IV | 47(58) | 76(42) | |
| Liver involvement | 0.027 | ||
| Yes | 8(9.9) | 5(2.8) | |
| No | 73(90.1) | 176(97.2) | |
| Spleen involvement | 0.024 | ||
| Yes | 12(14.8) | 11(6.1) | |
| No | 69(85.2) | 170(93.9) | |
| LDH increase | 0.89 | ||
| > normal | 40(49.4) | 91(50.3) | |
| normal | 41(50.6) | 90(49.7) | |
| Extra node involvement | 0.034 | ||
| ≤ 1 | 69(85.2) | 169(93.4) | |
| > 1 | 12(14.8) | 12(6.6) | |
| PS | 0.26 | ||
| ≤ 1 | 76(93.8) | 162(89.5) | |
| > 1 | 5(6.2) | 19(10.5) | |
| IPI | 0.99 | ||
| 0,1 | 46(57) | 103(57) | |
| 2,3,4 | 35(43) | 78(43) | |
| Chemotherapy | 0.69 | ||
| Range | 1–20 | 1–16 | |
| Median | 6 | 6 | |
| Radiation | 0.61 | ||
| Yes | 26(32.1) | 64(35.4) | |
| No | 55(67.9) | 117(64.6) | |
| Response | 0.24 | ||
| CR | 43(53) | 103(61.7) | |
| PR | 31(38) | 48(28.7) | |
| SD | 5(6) | 8(4.8) | |
| PD | 3(3) | 8(4.8) | |
| NA | 14 | ||
| Hepatic dysfunction before chemotherapy | 17(21) | 10(5.5) | < 0.001 |
| Hepatic dysfunction during chemotherapy | 40(49.4) | 30(16.6) | < 0.001 |